@article {18763,
	title = {Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.},
	journal = {Allergy},
	volume = {75},
	year = {2020},
	pages = {1023-1042},
	author = {I, Agache and Rocha C, and Beltran J, and Song Y, and Posso M, and Sol{\`a} I, and Alonso-Coello P, and Akdis  C, and Akdis M, and Canonica GW and Casale T, and Chivato T, and Corren  J, and Del Giacco S, and Eiwegger T, and Firinu  D, and Gern JE, and Hamelmann E and Hanania  N, and M{\"a}kel{\"a}  M, and Mart{\'\i}n I, and Nair  P, and O{\textquoteright}Mahony L, and Papadopoulos NG and A, Papi, and Park HS, and P{\'e}rez de Llano L, and Quirce  S, and Sastre  J, and Shamji  M, and Schwarze, and Canelo-Aybar C, and Palomares O, and Jutel M.}
}
